Sugi Predict

Sugi Predict / Targets / ALG3

ALG3

Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase · Q92685 · ALG3 on Sugi Atlas →

0 patent compounds predicted against ALG3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ALG3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen PHASE4COMPLETED
Austrian Multivessel Taxus-Stent Registry PHASE4COMPLETED
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease PHASE3COMPLETED
Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease PHASE3RECRUITING
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms PHASE3COMPLETED
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis PHASE3COMPLETED
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy PHASE2UNKNOWN
Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery PHASE2COMPLETED
Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases PHASE2RECRUITING
The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer PHASE1/PHASE2RECRUITING
A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) PHASE1/PHASE2RECRUITING
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer PHASE1COMPLETED
A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations PHASE1COMPLETED
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer PHASE1COMPLETED
A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer PHASE1RECRUITING
A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies) PHASE1COMPLETED
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing nanCOMPLETED
Pain Outcomes Associated With Exogenous Hormone Therapy in Adults nanRECRUITING
Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE) nanRECRUITING
A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure nanUNKNOWN
Diagnostic Accuracy and Performance of 18F-PSMA-1007 nanCOMPLETED
Early Detection and Follow-Up of Patients With Fabry's Disease nanUNKNOWN
Tendinopathy Education on the Achilles nanCOMPLETED
An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 nanUNKNOWN
Biomarkers of CASH nanACTIVE_NOT_RECRUITING
From PSA to Stockholm3: Study Part 1 nanACTIVE_NOT_RECRUITING
Digital Treatment for Migraines - a Feasibility Study nanCOMPLETED
DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy nanACTIVE_NOT_RECRUITING
Theranostic Applications of Radionuclides in Prostate Cancer nanRECRUITING
Mechanisms of Myocardial Infarction in Women With Non Obstructive Coronary Artery Disease nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ALG3 binder may also engage these)

ProteinNameSimilarity
Q8K2A8 — 0.997 Q8K2A8 →
Q5F380 — 0.979 Q5F380 →
Q7T310 — 0.976 Q7T310 →
Q9BV10 — 0.974 Q9BV10 →
Q3TAE8 — 0.973 Q3TAE8 →
Q802T2 — 0.971 Q802T2 →
Q3T1L5 — 0.971 Q3T1L5 →
A0A8C2M425 — 0.968 A0A8C2M425 →
Q5KR61 — 0.968 Q5KR61 →
SOAT2 Sterol O-acyltransferase 2 0.967 landscape →
Q8VDB2 — 0.966 Q8VDB2 →
O82244 — 0.966 O82244 →
Q9Y6A1 — 0.965 Q9Y6A1 →
Q8C3X8 — 0.964 Q8C3X8 →
Q7SXZ1 — 0.963 Q7SXZ1 →
Q9NUD9 — 0.963 Q9NUD9 →
Q8R2R1 — 0.963 Q8R2R1 →
Q7TPN3 — 0.963 Q7TPN3 →
Q9EQY6 — 0.963 Q9EQY6 →
Q9BU23 — 0.962 Q9BU23 →
Q5NVS8 — 0.961 Q5NVS8 →
Q5RAH7 — 0.961 Q5RAH7 →
Q7TQM4 — 0.960 Q7TQM4 →
Q500W7 — 0.960 Q500W7 →
O88908 — 0.960 O88908 →
Q71KT5 — 0.960 Q71KT5 →
Q5EA10 — 0.959 Q5EA10 →
A1L1J9 — 0.959 A1L1J9 →
Q921Q3 — 0.959 Q921Q3 →
O77759 — 0.959 O77759 →